Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prochlorperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 10/20 | 0.98 |
| ▸ | MAPT | P10636 | 8/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.98 |
| ▸ | LMNA | P02545 | 7/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.98 |
| ▸ | HTR2A | P28223 | 7/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.98 |
| ▸ | HRH1 | P35367 | 7/20 | 0.98 |
| ▸ | DRD3 | P35462 | 7/20 | 0.98 |
| ▸ | HTR1A | P08908 | 7/20 | 0.98 |
| ▸ | TP53 | P04637 | 6/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 6/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prochlorperazine SCHEMBL1041250 | 1.00 | DRD2 (0.98) | DRD2MAPTMAPK1LMNASMN1; SMN2 | |
| Prochlorperazine SCHEMBL29369439 | 0.99 | DRD2 (1.00) | DRD2MAPTMAPK1LMNASMN1; SMN2 | |
| Prochlorperazine SCHEMBL18429 | 0.99 | DRD2 (1.00) | DRD2MAPTMAPK1LMNASMN1; SMN2 | |
| Prochlorperazine SCHEMBL29358207 | 0.99 | DRD2 (1.00) | DRD2MAPTMAPK1LMNASMN1; SMN2 | |
| Prochlorperazine SCHEMBL14126977 | 0.99 | DRD2 (1.00) | DRD2MAPTMAPK1LMNASMN1; SMN2 | |
| Prochlorperazine SCHEMBL133595 | 0.98 | DRD2 (0.98) | DRD2MAPTMAPK1LMNASMN1; SMN2 | |
| Perphenazine SCHEMBL5307579 | 0.93 | MAPT (0.91) | DRD2MAPTMAPK1LMNASMN1; SMN2 | |
| Perphenazine SCHEMBL28086447 | 0.93 | MAPT (0.91) | DRD2MAPTMAPK1LMNASMN1; SMN2 | |
| Prochlorperazine SCHEMBL10891828 | 0.92 | MAPT (0.90) | DRD2MAPTMAPK1LMNASMN1; SMN2 | |
| SCHEMBL13485632 | 0.92 | MAPT (0.86) | DRD2MAPTMAPK1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070031340-A1 | Thin-film drug delivery article and method of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-08 | — | — | US | claimed |
| US-20190336437-A1 | Drug Condensation Aerosols And Kits | ALEXZA PHARMACEUTICALS, INC. | 2019-11-07 | — | — | US | disclosed |
| US-10350157-B2 | Drug condensation aerosols and kits | ALEXZA PHARMACEUTICALS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20160374937-A1 | Drug Condensation Aerosols And Kits | ALEXZA PHARMACEUTICALS, INC. | 2016-12-29 | — | — | US | disclosed |
| US-9440034-B2 | Drug condensation aerosols and kits | ALEXZA PHARMACEUTICALS, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9211382-B2 | Drug condensation aerosols and kits | ALEXZA PHARMACEUTICALS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150250800-A1 | ACUTE TREATMENT OF HEADACHE WITH PHENOTHIAZINE ANTIPSYCHOTICS | ALEXZA PHARMACEUTICALS, INC. | 2015-09-10 | — | — | US | disclosed |
| US-20140060525-A1 | Drug Condensation Aerosols And Kits | ALEXZA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130032139-A1 | Drug Condensation Aerosols And Kits | ALEXZA PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-8235037-B2 | Impermeable heat-conductive substrate coated with alprazolam, fentanyl, loxapine, prochlorperazine or zaleplon and a heat source that can supply heat to the substrate at a rate that can vaporize all or a portion of the coated drug within a period of 2 seconds | ALEXZA PHARMACEUTICALS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20080038363-A1 | Administering such as alprazolam via a dry powder inhaler; cutting effective dosage level by half; central nervous system disorders | ALEXZA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20070286816-A1 | Drug and excipient aerosol compositions | ALEXZA PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070122353-A1 | Condensation aerosols having little or no pyrolysis degradation; vaporization | HALE RON L | 2007-05-31 | — | — | US | disclosed |
| US-20070028916-A1 | Rapid-heating drug delivery article and method of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-08 | — | — | US | disclosed |
| US-20070031340-A1 | Thin-film drug delivery article and method of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-08 | — | — | US | disclosed |
| US-20060193788-A1 | Acute treatment of headache with phenothiazine antipsychotics | ALEXZA PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| US-7090830-B2 | Drug condensation aerosols and kits | ALEXZA PHARMACEUTICALS, INC. (US) | 2006-08-15 | — | — | US | disclosed |
| CN-1726037-A | Treatment of headache with antipsychotics delivered by inhalation | ALEXZA MOLECULAR DELIVERY CORP (US) | 2006-01-25 | — | — | CN | disclosed |
| US-20040099269-A1 | Drug condensation aerosols and kits | ALEXZA MOLECULAR DELIVERY CORPORATION (US) | 2004-05-27 | — | — | US | disclosed |
| US-20040101481-A1 | Acute treatment of headache with phenothiazine antipsychotics | ALEXZA MOLECULAR DELIVERY CORPORATION (US) | 2004-05-27 | — | — | US | disclosed |